Publications

The Impact of Amyloid and Tau PET on Alzheimer Disease Diagnostics: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2025 Nov 5:1-14.

Calibration of multisite raters for prospective visual reads of amyloid PET scans. Alzheimers Dement. 2025 Oct;21(10):e70732.

[11C]Carfentanil PET Whole-Body Imaging of Mu-Opioid Receptors: A First In-Human Study. 2025 Jul. J Nucl Med 66(7): 1112-1118. 

Pilot Study of [11C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer. Cells. 2025 Jul 26;14(15):1157.

Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain . 2025 May 13;148(5):1577-1587. 

Total-body imaging of mu-opioid receptors with [11C]carfentanil in non-human primates.  Eur J Nucl Med Mol Imaging. 2024 Sep. 51(11): 3273-3283.

Molecular Imaging of Pulmonary Inflammation in Users of Electronic and Combustible Cigarettes: A Pilot Study. J Nucl Med. 2023 May;64(5):797-802.

[18F]NOS PET brain imaging suggests elevated neuroinflammation in idiopathic Parkinson’s disease. Cells. 2022 Sep; 11(19):3081.

Self- and partner-reported subjective memory complaints: association with objective cognitive impairment and risk of decline. JAD reports 2022 Jul; 6(1): 411-430.

Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced parkinsonism. npj Parkinson's Disease. 2022 Apr; 8(1):53.

Rates of longitudinal change in 18 F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.  Alzheimers Dement 2022 Jun;18(6):1235-1247.

Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Ann Neurol. 2021 Nov;90(5):751-762.

Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology.  Nucl Med Commun. 2021 Nov 1;42(11):1261-1269.

Quantitative [18] FDG PET asymmetry features predict long-term seizure recurrence in refractory epilepsy. Epilepsy Behav 2021 Mar;116:107714.

Frontiers in Neuroscience Imaging: Whole-Body PET. PET Clin. 2021 Jan;16(1):137-146.

Alzheimer’s Disease Neuroimaging Initiative. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. Neurobiol Aging. 2020 Dec;96:137-147.

Arterial spin labeling versus 18 F-FDG-PET to identify mild cognitive impairment.  Neuroimage Clin. 2020;25:102146. 

Flare Phenomenon in O-(2-[ 18 F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas: Potential Contribution from Postoperative Ischemia.  J Nucl Med. 2020 Dec;61(12):1851-1852.  

PennPET Explorer: Human Imaging on a Whole-Body Imager. J Nucl Med. 2020 Jan;61(1):144-151.

Selectivity of probes for PET imaging of dopamine D3 receptors. Neurosci Lett. 2019 Jan 19;691:18-25.

Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp. 2018 Feb;39(2):691-708.

18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease. J Nucl Med. 2018 Feb;59(2):299-306.

Diagnostic Performance of the Visual Reading of 123I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia. J Nucl Med. 2017 Nov;58(11):1821-1826.

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One. 2017 May 25;12(5): e0177924.

Olfactory Impairment Predicts Underlying Dopaminergic Deficit in Presumed Drug-Induced Parkinsonism.Mov Disord Clin Pract. 2016 Nov 28;4(4):603-606.

Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. J Nucl Med. 2015 Nov;56(11):1724-9.

Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia? Acad Radiol. 2015 Aug;22(8):988-94.

Alzheimer's Disease Neuroimaging Initiative. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. AJNR Am J Neuroradiol. 2015 Jul;36(7):1237-44.

Taste function in early stage treated and untreated Parkinson's disease. J Neurol. 2015 Mar;262(3):547-57.

Point pressure sensitivity in early stage Parkinson's disease. Physiol Behav. 2015 Jan;138:21-7.

Suprathreshold odor intensity perception in early-stage Parkinson's disease. Mov Disord. 2014 Aug;29(9):1208-12.

Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014 Dec;55(12):2003-11.

An overview of PET neuroimaging. Semin Nucl Med. 2013 Nov;43(6):449-61.